THE KING HYPOTHESIS: A SURGEON'S PANORAMIC VIEW Reclassifying All Clinically Detectable Tumors as Secondaries of a Hidden Systemic Stem-Cell Axis A Theory, A Hypothesis, and A Global Call for Collaboration

Keywords: Cancer stem cell; KING cell; metastasis; primary tumor; tumor self-seeding; cell fusion; breast cancer; systemic disease; hypothesis; spontaneous regression ABSTRACT For more than a century, oncology has classified the first clinically palpable tumor as the primary tumor, regional lymph nodes as secondary, and distant lesions as metastases. This classification has guided surgery, yet we continue to lose our never-ending war against cancer. As a fighting surgeon, not a molecular biologist, I present here a clinical, panoramic, inverted view born from the operating room, not from the laboratory. I hypothesize that what we call the primary tumor is, in fact, the first clinically detectable secondary. In this model, the palpable breast mass is the first clinically detectable secondary (CDS-1), the palpable axillary nodes are the second clinically detectable secondary (CDS-2), and hemorrhagic pleural effusion is the third clinically detectable secondary (CDS-3). A fourth and fifth secondary will inevitably appear if the patient survives long enough. I postulate the existence of a hidden, systemic, supreme metastasis-initiating stem cell - the KING - which masters and orchestrates all its organ-specific daughter colonies. The KING never dies, survives till the end, and continuously recruits and regenerates new wild soldiers to invade remote organs. I further postulate a Primary-KING Metastatic Axis: a coded signaling axis between the KING and its progeny, which fuels local recurrence, metachronous metastases, and metastasis-to-metastasis seeding. Fusion of malignant cells from different organs explains anaplasia as fused double primaries. This is presented explicitly as a theory and hypothesis, not as proven fact. It is falsifiable and testable. I issue a global call for collaboration to molecular biologists, oncologists, immunologists, bioinformaticians, and surgeons to test, refute, or refine it. If validated, targeting the KING and cutting its axis could shift oncology from minimally invasive surgery toward no surgery at all for cancer.